Cryoport completed the acquisition of CRYOPDP for $58m.

Cryoport, a provider of temperature-controlled supply chain solutions for the life sciences industry, completed the acquisition of CRYOPDP, a provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets, for $58m. “Cryoport’s culture, mission and strategy are closely aligned with CRYOPDP and we are pleased to join the Cryoport family at a time when the cell and gene therapy market is experiencing rapid growth, with many drugs approaching commercial approval. Collectively, we believe we will be able to compete for the entire supply chain support needs of life sciences companies from a local to global basis, providing the world’s most advanced temperature-controlled supply chain solutions. It is truly an exciting time. Both companies’ existing, and future, client bases will be able to benefit from our expanded capabilities, which include shipping, distribution, bioservices, custom controlled temperature logistics, kitting, and cell and gene therapy fulfilment across the full spectrum of temperature ranges,” Cedric Picaud, CRYOPDP Chief Executive Officer.